- Notice of Results
- MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
- Total Voting Rights and Block Listing Return
- Signing of Strategic Platform License
- MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
- Exercise of options and PDMR dealing
- Grant of Options, RSUs and PSUs and PDMR Dealing
- Filing of form 10-K for FY ended December 31, 2023
- Reports Q4 & FY 2023 Financial Results
- MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
More ▼
Key statistics
On Friday, MaxCyte Inc (MXCT:LSE) closed at 295.00, 73.53% above the 52 week low of 170.00 set on Oct 05, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 295.00 |
---|---|
High | 336.00 |
Low | 336.00 |
Bid | 290.00 |
Offer | 300.00 |
Previous close | 295.00 |
Average volume | 13.05k |
---|---|
Shares outstanding | 104.40m |
Free float | 98.17m |
P/E (TTM) | -- |
Market cap | 385.22m USD |
EPS (TTM) | -0.3675 USD |
Data delayed at least 20 minutes, as of Apr 26 2024 16:20 BST.
More ▼